Companies › GrandPharma (China)
2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rivoceranib Vascular endothelial growth factor receptor 2 inhibitor | KDR | Phase 2 | HCC | Dec 2027 |
| Yttrium [90Y] Microsphere Injection Yttrium-90 radioembolization via hepatic artery | – | Phase 2 | HCC | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07334483 | Yttrium [90Y] Microsphere Injection | Phase 2 | HCC | Oncology | Dec 2027 |
| NCT07334483 | Rivoceranib | Phase 2 | HCC | Oncology | Dec 2027 |
Hutchmed Exelixis Merck & Co. (MSD) Jiangsu HengRui Medicine Chia Tai Tianqing Pharmaceutical Group Takeda AO GENERIUM Chipscreen Biosciences Avalyn Pharma Mannkind
Guangzhou Virotech Pharmaceutical Criterium Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.